NCT00132379View on ClinicalTrials.gov

ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

ABR-217620

10.3, 16.5 or 22 mcg/kg, IV, daily 5 minute bolus injection for 4 consecutive day per cycle; up to 6 cycles

DRUG

docetaxel

75mg/m\^2, IV, single 60 minute infusion, beginning on Day 5 then every third week

Trial Locations (4)

19111

Fox Chase Cancer Center, Philadelphia

194354

City Multifield Hospital #2, City Center of Intensive Pulmonology and Thoracic Surgery, Saint Petersburg

197022

St. Petersburg Pavlov State Medical University, Saint Petersburg

Unknown

Onkologisk Klinik, Rigshospitalet, Copenhagen

Sponsors

Lead Sponsor

Active Biotech AB
All Listed Sponsors
lead

Active Biotech AB

INDUSTRY